Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks
Not Applicable
Active, not recruiting
- Conditions
- Abdominal Aortic Aneurysm
- Interventions
- Device: IMPEDE-FX Embolization Plug
- Registration Number
- NCT04227054
- Lead Sponsor
- Shape Memory Medical, Inc.
- Brief Summary
To determine the safety and efficacy of IMPEDE-FX Embolization Plug and/or IMPEDE-FX Rapid Fill to fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
- ≥18 years of age
- A candidate for elective EVAR of an infrarenal aortic aneurysm ≥5.5 cm in diameter in men and ≥5.0 cm in women
Exclusion Criteria
- An inability to provide informed consent
- Enrolled in another clinical study
- Concomitant iliac artery ectasia or aneurysm (common iliac artery diameter >24 mm)
- Patent AAA sac feeding vessels (within the sac) >4 mm in diameter
- Volume of AAA sac to be filled after stent graft placement <30 mL or >135 mL, based on pre-procedure CTA (i.e. aortic flow volume exclusive of stent graft volume)
- Use of aortic stent grafts other than the Gore Excluder AAA Endoprosthesis, Cook Zenith Flex AAA Endovascular Graft, Medtronic Endurant II Stent Graft, or Endologix Ovation Alto Abdominal Stent Graft System to treat the AAA
- Planned use of the chosen stent graft outside its instructions for use (IFU)
- Planned use of fenestrated or chimney stent grafts
- Study participants in which stent graft placement is abandoned for any reason, and/or in which the investigator decides, during the course of the stent graft placement, that the study procedure may not be appropriate
- Planned use of embolic devices other than the investigational product to embolize the AAA sac
- Vascular disease and/or anatomy that preclude the safe access and positioning of a catheter to deliver the investigational product into the AAA sac
- Ruptured, leaking, or mycotic (infected) aneurysm
- Aneurysmal disease of the descending thoracic aorta
- Coagulopathy or uncontrolled bleeding disorder
- Long-term (>6 months prior to the procedure) use of direct oral anticoagulant or any vitamin K antagonist anticoagulant use
- Serum creatinine level >2.5 mg/dL;
- Cerebrovascular accident within 3 months prior to the procedure
- Myocardial infarction and/or major heart surgery within 3 months prior to the procedure
- Atrial fibrillation that is not well rate controlled
- Unable or unwilling to comply with study follow-up requirements
- Life expectancy of <2 years post-procedure
- Known hypersensitivity or contraindication to platinum, iridium, or polyurethane
- A condition that inhibits radiographic visualization during the implantation procedure
- History of allergy to contrast medium that cannot be managed medically
- Uncontrolled co-morbid medical condition, including mental health issues, that would adversely affect participation in the study
- Pregnant or a lactating female. For females of child-bearing potential, based on a positive pregnancy test within 7 days prior to the procedure or refusal to use a medically accepted method of birth control for the duration of the study
- Prisoner or member of other vulnerable population.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Intervention IMPEDE-FX Embolization Plug -
- Primary Outcome Measures
Name Time Method Incidence of related major adverse events (MAEs) 30 days post-procedure Incidence of related major adverse events (MAEs)
Efficacy - Technical Success Immediately after the intervention Technical success, defined as filling of the residual flow lumen of the AAA sac with investigational products
- Secondary Outcome Measures
Name Time Method Efficacy - Open repair 2 years post-procedure Rate of conversion to open AAA repair
Incidence of related major adverse events (MAEs) 2 years post-procedure Incidence of related major adverse events (MAEs)
Incidence of related serious adverse events (SAEs) 2 years post-procedure Incidence of related serious adverse events (SAEs)
Efficacy - Type I and type III endoleaks 2 years post-procedure Incidence of type I and type III endoleaks
Efficacy - Reinterventions 2 years post-procedure Rate of other reinterventions related to the AAA sac growth and/or complications
Efficacy - Type II endoleaks 2 years post-procedure Incidence of type II endoleaks
Efficacy - AAA sac diameter/volume 2 years post-procedure Change in AAA sac diameter/volume
Trial Locations
- Locations (2)
Auckland City Hospital
🇳🇿Auckland, New Zealand
Waikato Hospital
🇳🇿Hamilton, New Zealand